Anti-epileptogenic agents
AssigneeQueen's University at Kingston
InventorsDonald E. Weaver, Paul H. Milne, Christopher Y. K. Tan, John R. Carran
Life of this patent
Estimating the term…
Abstract
Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and epileptogenesis. Methods for preparing the compounds of the invention are also described.
Claims36
α-(4-tert-butylcyclohexyl)-β-alanine, or an ester or pharmaceutically acceptable salt thereof.
α-(4-phenylcyclohexyl)-β-alanine, or an ester or pharmaceutically acceptable salt thereof.
α-cyclododecyl-β-alanine, or an ester or pharmaceutically acceptable salt thereof.
β-(p-methoxyphenethyl)-β-alanine, or an ester or pharmaceutically acceptable salt thereof.
β-(p-methylphenethyl)-β-alanine, or an ester or pharmaceutically acceptable salt thereof.
β-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-β-alanine, or an ester or pharmaceutically acceptable salt thereof.
β-(3-pentyl)-β-alanine or an ester or pharmaceutically acceptable salt thereof.
β-(4-methylcyclohexyl)-β-alanine or an ester or pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprsing α-(4-tert-butylcyclohexyl)-β-alanine, or an ester or pharmaceutically acceptable salt thereof, in an amount effective for inhibiting epileptogenesis, and a pharmaceutically acceptable vehicle.
A pharmaceutical composition comprising α-(4-phenylcyclohexyl)-β-alanine, or an ester or pharmaceutically acceptable salt thereof, in an amount effective for inhibiting epileptogenesis and a pharmaceutically acceptable vehicle.
A pharmaceutical composition comprising α-cyclododecyl-β-alanine, or an ester or pharmaceutically acceptable salt thereof, in an amount effective for inhibiting epileptogenesis, and a pharmaceutically acceptable vehicle.
A pharmaceutical composition compnsing β-(p-methoxyphenethyl)-β-alanine, or an ester or pharmaceutically acceptable salt thereof, in an amount effective for inhibitlnst epileptgoenesis, and a pharmaceutically acceptable vehicle.
A pharmaceutical composition comprising α-(p-methylphenethyl)-β-alanine, or an ester or pharmaceutically acceptable salt thereof, in an amount effective for inhibiting epileptogenesis, and a pharmaceutically acceptable vehicle.
A pharmaceutical composition comprising β-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-β-alanine, or an ester or pharmaceutically acceptable salt thereof, in an amount effective for inhibiting epileptogenesis, and a pharmaceutically acceptable vehicle.
A pharmaceutical composition comprising β-(3-pentyl)-β-alanine or an ester or pharmaceutically acceptable salt thereof, in an amounlt effective for inhibiting epileptogenesis and a pharmaceutically acceptable vehicle.
A pharmaceutical composition comprising β-(4-methylcyclohexyl)-β-alanine or an ester or pharmaceutically acceptable salt thereof, in an amount effective for inhibiting elileptogenesis, and a pharmaceutically acceptable vehicle.
A pharmaceutical composition comprising β-(4-influoromethylphenyl)-β-alanine or an ester or pharmaceutically acceptable salt thereof, in an amount effective for inhibiting epileptogenesis, and a pharmaceutically acceptable vehicle.
A method for inhibiting epileptogenesis, comprising administering to a subject in need thereof an effective amount of an anti-epileptogenic agent which is a β-amino acid or an ester or salt thereof, such that epileptogenesis is inhibited in said subject.
A method for inhibiting epileptogenesis, comprising administering to a subject in need thereof an effective amount of an agent such that epileptogenesis is inhibited in said subject by a β-amino acid or an ester or salt thereof.
Dependencies are inferred from the claim text.